Arcturus Therapeutics (ARCT) News Today $15.73 -0.51 (-3.14%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT) and Madrigal Pharmaceuticals (MDGL)December 18 at 5:44 AM | markets.businessinsider.comArcturus Therapeutics: Promising COVID-19 Vaccine Advancements and Strategic Collaborations Justify Buy RatingDecember 17 at 7:42 PM | markets.businessinsider.comArcturus Therapeutics (NASDAQ:ARCT) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a research report on Tuesday.December 17 at 8:38 AM | marketbeat.comArcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 16 at 4:07 PM | finance.yahoo.comArcturus Therapeutics' (ARCT) "Overweight" Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a research report on Monday.December 16 at 8:37 AM | marketbeat.comFmr LLC Sells 112,516 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Fmr LLC lessened its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 20.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 443,008 shares of the biotechnology company's stock after selling 112,516December 12, 2024 | marketbeat.comWhy Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short SellersDecember 11, 2024 | finance.yahoo.comPositive Outlook for Arcturus Therapeutics Driven by Innovative Vaccine KostaiveDecember 6, 2024 | markets.businessinsider.comArcturus Therapeutics (NASDAQ:ARCT) Trading Up 13.3% - Here's What HappenedArcturus Therapeutics (NASDAQ:ARCT) Trading Up 13.3% - Should You Buy?December 6, 2024 | marketbeat.comPortolan Capital Management LLC Sells 355,763 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Portolan Capital Management LLC reduced its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 73.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 129,144 shares of the biotechDecember 5, 2024 | marketbeat.comPDT Partners LLC Buys Shares of 75,144 Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)PDT Partners LLC bought a new position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 75,144 shares of the biotechnology compaDecember 1, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have been assigned an average rating of "Buy" from the eight research firms that are currently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating and one has given a stronNovember 30, 2024 | marketbeat.comGSA Capital Partners LLP Sells 52,213 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)GSA Capital Partners LLP trimmed its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 84.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,417 shares of the biotechnology company's stock aftNovember 25, 2024 | marketbeat.comArcturus Therapeutics to Present at Jefferies London Healthcare ConferenceNovember 18, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Acquired by Sumitomo Mitsui Trust Group Inc.Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 45.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,275,715 shares of theNovember 16, 2024 | marketbeat.comArcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim DataNovember 14, 2024 | seekingalpha.comMeiji Seika Pharma Announces Investment in ARCALIS, Inc.November 14, 2024 | businesswire.comArcturus Therapeutics: Overcoming Challenges and Poised for European ExpansionNovember 13, 2024 | markets.businessinsider.comArcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical TrialNovember 11, 2024 | businesswire.comArcturus Therapeutics: Strategic Growth and Robust Pipeline Justify Buy RatingNovember 11, 2024 | markets.businessinsider.comArcturus Therapeutics: Promising Future with Key Developments and Financial StabilityNovember 11, 2024 | markets.businessinsider.comHC Wainwright Has Positive Outlook of ARCT FY2028 EarningsArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Stock analysts at HC Wainwright raised their FY2028 earnings estimates for shares of Arcturus Therapeutics in a research note issued on Friday, November 8th. HC Wainwright analyst E. Arce now expects that the biotechnology companyNovember 11, 2024 | marketbeat.comArcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats ExpectationsNovember 10, 2024 | finance.yahoo.comQ3 2024 Arcturus Therapeutics Holdings Inc Earnings CallNovember 8, 2024 | finance.yahoo.comArcturus Therapeutics: Strong Buy Rating Backed by Promising Kostaive Sales and Promising Pipeline DevelopmentsNovember 8, 2024 | markets.businessinsider.comArcturus Therapeutics Reports Q3 2024 Financial Results and MilestonesNovember 8, 2024 | markets.businessinsider.comArcturus Therapeutics' (ARCT) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a research report on Friday.November 8, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Holdings Increased by ARK Investment Management LLCARK Investment Management LLC increased its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 6.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,101,038 shares of theNovember 8, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ...November 8, 2024 | finance.yahoo.comArcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline ProgressNovember 8, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | seekingalpha.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Buy" by BrokeragesArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has received an average rating of "Buy" from the eight brokerages that are covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buNovember 5, 2024 | marketbeat.comEmpire Life Investments Inc. Makes New $3.50 Million Investment in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Empire Life Investments Inc. purchased a new stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) in the third quarter, according to its most recent 13F filing with the SEC. The fund purchased 150,692 shares of the biotechnology company's stock, valued at approximatelyNovember 3, 2024 | marketbeat.comArcturus Therapeutics (ARCT) Set to Announce Quarterly Earnings on ThursdayArcturus Therapeutics (NASDAQ:ARCT) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Stock Passes Below Two Hundred Day Moving Average - Here's What HappenedArcturus Therapeutics (NASDAQ:ARCT) Stock Crosses Below Two Hundred Day Moving Average - Here's What HappenedNovember 1, 2024 | marketbeat.comIntellia Therapeutics: Assessing NTLA-2002’s Efficacy and Market Potential Amid Phase 2 Trial UpdatesOctober 25, 2024 | markets.businessinsider.comArcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 6.1% - Should You Sell?Arcturus Therapeutics (NASDAQ:ARCT) Trading Down 6.1% - Here's WhyOctober 24, 2024 | marketbeat.comInvesting in Arcturus Therapeutics Holdings (NASDAQ:ARCT) five years ago would have delivered you a 76% gainOctober 24, 2024 | finance.yahoo.comA slow start for self-amplifying mRNA vaccinesOctober 23, 2024 | finance.yahoo.comArcturus Therapeutics (NASDAQ:ARCT) Shares Down 5.8% Following Insider SellingArcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 5.8% Following Insider SellingOctober 17, 2024 | marketbeat.comPad Chivukula Sells 12,000 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) StockOctober 17, 2024 | insidertrades.comAQR Capital Management LLC Has $285,000 Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)AQR Capital Management LLC lessened its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 84.2% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 11,700 shares of the biotechnology company's stock after sellingOctober 17, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Pad Chivukula Sells 12,000 SharesArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) COO Pad Chivukula sold 12,000 shares of the business's stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the sale, the chief operating officer now owns 435,334 shares of the company's stock, valued at approximately $9,037,533.84. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.October 16, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest UpdateArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 4,600,000 shares, a decline of 12.0% from the September 15th total of 5,230,000 shares. Based on an average daily trading volume, of 389,800 shares, the days-to-cover ratio is presently 11.8 days. Approximately 18.6% of the company's shares are short sold.October 14, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 5.9% - Time to Sell?Arcturus Therapeutics (NASDAQ:ARCT) Trading Down 5.9% - Here's WhyOctober 10, 2024 | marketbeat.com29,499 Shares in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Bought by Squarepoint Ops LLCSquarepoint Ops LLC bought a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 29,499 shares of the biotechnology company's stock, valued at approximately $718,000.October 8, 2024 | marketbeat.comMillennium Management LLC Has $13.52 Million Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Millennium Management LLC boosted its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 250.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 555,024 shares of the bioteOctober 7, 2024 | marketbeat.comArcturus shares hold with Buy rating on Japan vaccine progressOctober 4, 2024 | uk.investing.comPositive Outlook for Arcturus Therapeutics’ Vaccine Production and Distribution Spurs Buy RatingOctober 4, 2024 | markets.businessinsider.comArcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.4% - Here's WhyArcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 3.4% - Here's WhyOctober 4, 2024 | marketbeat.com Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now ARCT Media Mentions By Week ARCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARCT News Sentiment▼0.300.71▲Average Medical News Sentiment ARCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARCT Articles This Week▼84▲ARCT Articles Average Week Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Galapagos News Xencor News Evotec News Arcutis Biotherapeutics News Nurix Therapeutics News Arcus Biosciences News Kiniksa Pharmaceuticals News Immunocore News Ocular Therapeutix News Mesoblast News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARCT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
